This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: AstraZeneca on Thursday announced plans to invest $15 billion in China over the next five years as the global pharmaceutical industry increasingly looks to the country for innovation. The investments through the year 2030 will “span the value chain,” including drug discovery, clinical development and manufacturing, AstraZeneca said. The British d ...